What is HC Wainwright’s Estimate for PDSB FY2026 Earnings?

PDS Biotechnology Corporation (NASDAQ:PDSB) – Equities researchers at HC Wainwright raised their FY2026 EPS estimates for PDS Biotechnology in a report released on Tuesday, March 31st. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of ($0.71) per share for the year, up from their prior estimate of ($0.73). The consensus estimate for PDS Biotechnology’s current full-year earnings is ($1.20) per share. HC Wainwright also issued estimates for PDS Biotechnology’s FY2027 earnings at ($0.77) EPS and FY2028 earnings at ($0.63) EPS.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of PDS Biotechnology in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, PDS Biotechnology has an average rating of “Hold” and a consensus target price of $9.00.

PDS Biotechnology Trading Up 4.7%

Shares of PDSB opened at $0.64 on Thursday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.09 and a current ratio of 2.09. The company has a market cap of $35.45 million, a price-to-earnings ratio of -0.85 and a beta of 1.20. The stock has a fifty day moving average price of $0.69 and a two-hundred day moving average price of $0.85. PDS Biotechnology has a 52-week low of $0.51 and a 52-week high of $1.92.

PDS Biotechnology (NASDAQ:PDSB) last released its quarterly earnings results on Monday, March 30th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.06.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC acquired a new position in PDS Biotechnology during the 4th quarter worth $25,000. Tempus Wealth Planning LLC increased its stake in shares of PDS Biotechnology by 29.3% in the 4th quarter. Tempus Wealth Planning LLC now owns 61,800 shares of the company’s stock valued at $48,000 after buying an additional 14,000 shares during the period. Watts Gwilliam & Co. LLC bought a new stake in shares of PDS Biotechnology during the second quarter worth $73,000. Marshall Wace LLP bought a new stake in shares of PDS Biotechnology during the second quarter worth $91,000. Finally, Jane Street Group LLC acquired a new position in shares of PDS Biotechnology during the second quarter valued at $92,000. Institutional investors own 26.84% of the company’s stock.

About PDS Biotechnology

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.